FindMyKOL
Clinical trialNCT01412359Approved, for, marketingExpanded Access

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury

NCT01412359 is an expanded access program sponsored by Jeffrey Rudolph. As of 21 Nov 2026, it has the registry status "Approved for marketing". It studies Omegaven® in Total Parenteral Nutrition-induced Cholestasis. The registry lists 1 site in 1 country.

SponsorJeffrey RudolphTotal Parenteral Nutrition-induced Cholestasis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01412359
FieldValue
Registry IDNCT01412359
StatusApproved for marketing
Study typeExpanded access program
Lead sponsorJeffrey Rudolph
Registered sites1
Countries1
ConditionsTotal Parenteral Nutrition-induced Cholestasis
DrugsOmegaven®
Last update posted24 Apr 2019

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall purpose of this study is to determine if replacing standard soybean oil based fat emulsions with Omegaven®, a fish oil based fat emulsion, can reverse or prevent the progression of parenteral nutrition associated cholestasis. It is a compassionate use protocol for patients who already have significant cholestasis related to parenteral nutrition.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States1 site
  • Children's Hospital of Pittsburgh of Upmc

    Pittsburgh

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Omegaven®
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01412359

Each answer restates registry values shown on this page.

What is NCT01412359?

NCT01412359 is an expanded access program sponsored by Jeffrey Rudolph. It studies Omegaven® in Total Parenteral Nutrition-induced Cholestasis.

Who leads NCT01412359?

The registry names Jeffrey A Rudolph, MD (principal investigator, University of Pittsburgh) as the overall official.

Where does NCT01412359 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01412359 study?

The registered drug and biological interventions are Omegaven®.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.